Ceftolozane/Tazobactam for the Treatment of Osteomyelitis Due to Multidrug-Resistant Pseudomonas aeruginosa

We conducted a retrospective study of 18 patients who were treated with ceftolozane/tazobactam (C/T) for greater than 48 hours for multidrug-resistant Pseudomonas aeruginosa (MDR-PA) osteomyelitis. Osteomyelitis was diagnosed by imaging, presence of systemic inflammatory signs and symptoms, elevated C-reactive protein, and positive culture for MDR-PA. Clinical cure was defined as complete or partial resolution of signs and symptoms of infection without need for escalation of antimicrobials during inpatient and outpatient therapy. The cohort was mostly male (81.2%) with a median age of 58.5 (53.5–68.5) years. The majority had polymicrobial osteomyelitis (77.8%) and a previous episode of osteomyelitis (83.3%). Clinical cure was achieved in 50% of patients, and C/T was well tolerated. These preliminary data suggest C/T maybe an option for treating patients with MDR-PA osteomyelitis, but more data are needed.
Source: Infectious Diseases in Clinical Practice - Category: Infectious Diseases Tags: Original Articles Source Type: research